Dated: 18 January 2021 WIERANA MICHANA MORNING NEWSLETTER

| Indices | СМР | %1D |
|--------------|-------|-------|
| Sensex | 49035 | -1.11 |
| Nifty | 14434 | -1.11 |
| BSE-Midcap | 18905 | -1.25 |
| BSE-Smallcap | 18682 | -1.06 |
| SGX Nifty | 14417 | -0.29 |
| | | |

Market Outlook

Indian markets are expected to open flat in a negative zone following global cues and trade in ranged mood before making the next move. All eyes on earnings and expectations on budget 2021 which will keep markets volatile. Technically index has formed bearish candle on the daily and Doji kind of pattern on the weekly scale as the closing was near its opening levels. A long negative candle was also formed with minor lower shadow. Technically, these pattern could indicate profit booking from the highs. We expect Nifty to show upside bounce to retest the new high of 14,653 in the coming week. On the flip side, a sharp follow-through weakness in the next 1-2 sessions is expected. On daily charts, the key support levels for the Nifty are placed at 14,321, followed by 14,209. If the index moves up, the key resistance levels to watch out for are 14,581 and 14,729.

| Index | FY21 | FY22E | FY23E |
|------------|------|-------|-------|
| Sensex EPS | 1550 | 1736 | 2031 |
| P/E | 32 | 28 | 24 |
| Nifty EPS | 501 | 551 | 645 |
| P/E | 29 | 26 | 22 |
| | | | |

| Global Indices | Current Value | %1D |
|-------------------|------------------|-------|
| DowJones | 30814 | -0.57 |
| Nasdaq | 12998 | -0.87 |
| DAX | 13788 | -1.44 |
| Nikkei 225 | 28303 | -0.76 |
| FTSE 100 | 6736 | -0.97 |
| Hang Seng | 28694 | 0.42 |
| Shanghai | 3572 | 0.16 |
| Straits Times | 2987 | -0.60 |

| Trading activity in cash Rs Cr | | | |
|--------------------------------|------|--------|-------|
| Date 15 Jan | Net | MTD | FY21 |
| FII | 971 | 16900 | 69821 |
| DII | -942 | -12323 | 13880 |

| Forex Rate | | |
|------------|-------|--------|
| USD/INR | 73.13 | 0.01% |
| EUR/INR | 88.65 | -0.21% |
| GBP/INR | 99.84 | 0.14% |
| JPY/INR | 70.38 | 0.15% |

| Corporate Action | | |
|------------------|-------------------|---------|
| Stock Name | Purpose | Ex Date |
| CESC | Interim Div Rs 45 | 22-Jan |

Top Domestic News

- HDFC Bank: The private sector lender on Saturday reported a 18% year-on-year (y-o-y) rise in net profit to ₹8,758.29 crore for the three months to December owing to higher net interest income and other income. The bank's net interest income grew 15.1% y-o-y to ₹16.317.6 crore. The Bank also said it has imposed a penalty of ₹10.20 lakh on its senior executive Jimmy Tata for selling his shares in violation of insider trading regulations.
- Reliance Industries: Billionaire Mukesh Ambani's Reliance Retail Ltd plans to embed its e-commerce app JioMart into WhatsApp within six months, allowing the 400 million users of India's most popular messaging service order products without having to leave the app, two officials aware of the development told Mint.
- Wipro: The IT services major said it has been selected as a strategic technology services partner by Fiat Chrysler Automobiles (FCA) to establish the latter's first Global Digital Hub in Hyderabad that will employ 1,000 people. The company on Saturday also said it has completed its ₹9,500-crore share buyback programme.
- **Piramal Enterprises**: The Piramal Group is set to acquire Dewan Housing Finance with 94% of the bankrupt home financier's creditors voting in favour of a bid by the Ajay Piramal-led group that has committed ₹38,250 crore to take over the assets of the mortgage lender. The NCLT will now have to approve the winning bid.
- Bharti Airtel: The telecom company is preparing to raise a billion dollars with an offer of perpetual bonds —
 securities with no maturity date for investors, The ET reported. Last week, the second-largest telecom company
 sounded out half a dozen MNC banks on the plan to tap offshore institutional investors.
 - Metropolis Healthcare: The diagnostic chain on Sunday said it will acquire Dr Ganesan's Hitech Diagnostic Centre Pvt Ltd in a cash and stock combination deal, to strengthen its leadership position in southern India. The company's board has approved the acquisition partly by way of cash consideration of ₹511 crore and partly by issuance of up to 4,95,000 equity shares of a face value of ₹2 each on a preferential basis, to the promoter group of Hitech.
 - **Dr Reddy's Laboratories:** The pharma major has received approval from the Drugs Control General of India to conduct phase 3 clinical trial for the Sputnik V vaccine for covid-19. The phase 3 study of Sputnik V will be conducted on 1,500 subjects as part of the randomised, double-blind, parallel-group, placebo-controlled study in the country, the Hyderabad-based firm said.

Global News

Wall Street's main indexes finished lower on Friday, weighed down by big U.S. banks after their earnings reports, while the energy fell sharply due to a regulatory probe into Exxon Mobil Corp. The Dow Jones Industrial Average fell 177.26 points, or 0.57%, to 30,814.26, the S&P 500 lost 27.29 points, or 0.72%, to 3,768.25 and the Nasdaq Composite dropped 114.14 points, or 0.87%, to 12,998.50. Asian share markets retreated from highs on Monday as disappointing news on U.S. consumer spending tempered risk sentiment ahead of a closely-watched reading on the health of the Chinese economy. Japan's Nikkei slipped 1% and away from a 30-year high.

| G-Sec Yield | Price | Change% |
|--------------------|-------|---------|
| 1yr Bond Yield | 3.71 | 0.45% |
| 10yr Bond Yield | 5.94 | 1.02% |

Results Calender18-Jan-21IBREAL, INDMART, IRB, RALLIS, SNOWMAN, TRIDENT

F&O Ban List BHEL, IDEA, SAIL



Disclaimer: Investments in securities market are subject to market risks, read all the related documents carefully before investing.

Mehta Equities Limited (MEL) has used information that is publically available and information developed in-house. Some of the information used in the document may have been obtained from members/persons other than the MEL and/or its affiliates and which may have been made available to MEL and/or its affiliates. MEL however does not warrant the accuracy, reasonableness and/or completeness of any information and does not take responsibility of updating any data/information. For data reference to any third party in this material, no such party will assume any liability for the same. All data/information used in preparation of this material is dated and may or may not be relevant at any time after the issuance of this material. MEL (including its affiliates) and any of its officers, directors, personnel and employees, shall not be liable for any loss, damage of any nature, including but not limited to direct, indirect, punitive, special, exemplary, consequential, as also any loss of profit in any arising form the use of this material in any manner. Nothing contained in this document shall be construed to be an investment advice/recommendation on an assurance of the benefits of investing. Recipient alone shall be fully responsible for any investment decision taken on the basis of this document.

MEHTA EQUITIES LTD

BSE: - Membership Clearing No. 122 - SEBI Regn. No. INB010683856, NSE: - Membership Clearing No. 13512- SEBI Regn. No. INB231351231, NSE FO SEBI Regn. No. INF231351231, CIN No: U65990MH1994PLC078478 MSEI: - Membership Clearing No. 51800 - SEBI Regn. No. INB261351234

Mehta Equities Limited, 903, 9th floor, Lodha Supremus, Dr.E. Moses Road, Worli Naka, Worli, Mumbai 400 018, India Tel: +91 22 6150 7101, Fax: +91 22 6150 7102 Email:<u>info@mehtagroup.in</u> Website:<u>www.mehtagroup.in</u>